回顾性分析一例寡转移前列腺腺癌伴有神经内分泌分化病例：患者为 63 岁的男性，前列腺穿刺活检为 Gleason 评分 5+4=9 分，伴神经内分泌分化的寡转移性前列腺癌，予以雄激素剥夺疗法联合根治性前列腺切除术，术后予以体外放射治疗，随访血清 PSA 降至非常低的水平。

We report a case of a 63-year-old man who presented with oligometastases of pT2N0M1b, Gleason score 5+4 prostatic adenocarcinoma and neuroendocrine differentiation. Patient underwent systemic therapy (Androgen deprivation therapy, ADT) combined with radical prostatectomy, with subsequent reduction of serum PSA to very low levels. The patient is currently on radiotherapy. This is a rare case of primary prostatic cancer (PCa) with oligometastatases.

收稿日期：2020-02-20  录用日期：2020-05-17

Received Date: 2020-02-20  Accepted Date: 2020-05-17

基金项目：德中机器人手术合作中心的建立（2017HH0106）

Foundation Item: “The establishment of Germany-China robot surgery cooperation center” (2017HH0106)

通讯作者：王东，Email: wangdong_robot@163.com

Corresponding Author: WANG Dong, Email: wangdong_robot@163.com

引用格式：周放，任尚青，范世达，等 . 综合治疗神经内分泌寡转移前列腺癌一例报道 [J]. 机器人外科学杂志，2020，1（2）:148-154.

Citation: ZHOU F, REN S Q, FAN S D, et al.Case report: systemic therapy combined with prostate-directed therapy of oligometastases of prostatic adenocarcinoma with neuroendocrine features[J].Chinese Journal of Robotic Surgery, 2020, 1 (2):148-154.

[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386. 

[2] Siegel R L, Miller K D, Jemal A.Cancer statistics[J].CA Cancer J Clin, 2015, 65(1): 5-29. 

[3] Tritschler S , Erdelkamp R , Stief C , et al. Neuroendokrines Prostatakarzinom[J].Der Urol, 2017, 56(11): 1475-1484. 

[4] Zaffuto E, Pompe R, Zanaty M, et al.Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: A seer database Analysis[J].Clin Genitourin Cacer, 2017, 15 (5): e793-e800. 

[5] Humphrey P A, Moch H, Cubilla A L, et al.The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours[J].Eur Urol, 2016, 70 (1): 106-119. 

[6] Epstein J I, Amin M B, Beltran H, et al.Proposed morphologic classification of prostate cancer with neuroendocrine differentiation[J].Am J Surg Pathol, 2014, 38 (6): 756-767. 

[7] Bhandari R, Vengaloor Thomas T, Giri S, et al.Small Cell Carcinoma of the Prostate: A Case Report and Review of the Literature[J].Cureus, 2020, 12 (2): e7074. 

[8] Basch E, Loblaw D A, Oliver T K, et al.Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline[J].J Clin Oncol, 2014, 32(30): 3436-3448. 

[9] Carroll P H, Mohler J L.NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection[J]. J Natl Compr Canc Netw, 2018, 16 (5S): 620-623. 

[10] Humphrey P A.Histological variants of prostatic carcinoma and their significance[J]. Histopathology, 2012, 60 (1): 59-74. 

[11] Weichselbaum R R, Hellman S.Oligometastases revisited[J].Nat Rev Clin Oncol, 2011, 8 (6): 378-382. 

[12] Weichselbaum R R, Hellman S.Oligometastases[J]. J Clin Oncol, 1995, 13 (1): 8-10. 

[13] Ward J F, Slezak J M, Blute M L, et al.Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15- year outcome[J]. BJU Int, 2005, 95 (6): 751-756. 

[14] Comen E, Norton L, Massagué J.Clinical implications of cancer self-seeding[J]. Nat Rev Clin Oncol, 2011, 8 (6): 369-377. 

[15] Leyh-Bannurah S R, Gazdovich S, Budäus L, et al. Local Therapy Improves Survival in Meta-static Prostate Cancer[J]. Eur Urol, 2017, 72 (1): 118-124. 

[16] Nouri M, Ratther E, Stylianou N, et al.Androgentargeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: An opportunity for intervention[J].Front Oncol, 2014. DOI: 10.3389/fonc.2014.00370 

[17] Matei D V, Renne G, Pimentel M, et al.Neuroendocrine differentiation in castration-resistant prostate cancer: A systematic diagnostic attempt[J].Clin Genitourin Cancer, 2012, 10(3): 164-173. 

[18] Beltran H, Tagawa S T, Park K, et al.Challenges in recognizing treatment-related neuroendocrine prostate cancer[J].J Clin Oncol, 2012, 30(36): e386-389. 

[19] Grigore A D, Ben-Jacob E, Farach-Carson M C.Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? [J].Front Oncol, 2015. DOI: 10.3389/fonc. 2015.00037 

[20] Nicolas M, Maria D S, Erik B.Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is another Standard. European Urology [J]. 2018, 73 (3): 316-321. 

[21] LU X, Horner J W, Paul E, et al.Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer[J]. Nature, 2017, 543 (7647): 728-732.